{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/irritable-bowel-syndrome/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 497ef8a3-f62a-4ee2-a629-0ee17ce4c283 --><h2>Changes</h2><!-- end field 497ef8a3-f62a-4ee2-a629-0ee17ce4c283 -->","summary":null,"htmlStringContent":"<!-- begin item 1377e1c4-3842-4293-a470-8a065ff719c5 --><!-- begin field fd2df1db-4748-4c21-8068-efc3a670141b --><p><strong>October 2020 </strong>— minor update. A history of drug abuse has been added to the contraindications and cautions for loperamide in line with updated manufacturer's SPC.</p><p><strong>March 2020 </strong>— Minor update. Brugada syndrome has been added to adverse effects of loperamide in line with updated manufacturer's SPC.</p><p><strong>September to October 2017</strong> — reviewed. A literature search was conducted in September 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone minor restructuring. The recommendations on the diagnosis and management of irritable bowel syndrome have been amended in line with current evidence, including the addition of linaclotide as a drug treatment option. Prescribing information has been expanded and updated.</p><!-- end field fd2df1db-4748-4c21-8068-efc3a670141b --><!-- end item 1377e1c4-3842-4293-a470-8a065ff719c5 -->","topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","lastRevised":"Last revised in October 2020","chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","fullItemName":"Management","slug":"management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"3085446a-becb-5144-ab61-c0efced5b1ea","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d89e6a68-72cb-4141-b2c8-a258cffe4255 --><h3>Previous changes</h3><!-- end field d89e6a68-72cb-4141-b2c8-a258cffe4255 -->","summary":null,"htmlStringContent":"<!-- begin item 40521799-d79a-4fa6-ac82-8012e9269126 --><!-- begin field 30d40d59-bd4f-4285-9f3b-6e2fd4005f6c --><p><strong>November 2016 </strong>— minor update. Adverse effects of loperamide have been updated to include information in a US Food and Drug Administration (FDA) Drug safety communication (2016), warning that exceeding the maximum dose can cause serious cardiac problems including QT interval prolongation, Torsades de pointes or other ventricular arrhythmias, syncope, and cardiac arrest.</p><p><strong>February 2013 </strong>— reviewed. A literature search was conducted in October 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>January 2012 </strong>— minor update. A link to the CKS topic on <em>Depression</em> for more information on prescribing selective serotonin reuptake inhibitors has been added to the Prescribing Information section. Issued in January 2012.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>April to August 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Selective serotonin reuptake inhibitors are now recommended as an alternative to tricyclic antidepressants if a tricyclic has previously been shown to be ineffective.</p><p><strong>June 2005 </strong>— reviewed. Validated in September 2005 and issued in November 2005.</p><p><strong>April 2002 </strong>— reviewed and updated to include the British Society of Gastroenterology guidelines, and The Primary Care Society for Gastroenterology guidelines. Validated in June 2002 and issued in July 2002.</p><p><strong>June 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field 30d40d59-bd4f-4285-9f3b-6e2fd4005f6c --><!-- end item 40521799-d79a-4fa6-ac82-8012e9269126 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}